Last updated: March 2, 2026
Case Overview
AbbVie Inc. filed patent infringement litigation against Hetero USA Inc. in the United States District Court for the District of Delaware. The case focuses on patent rights related to AbbVie's blockbuster drug, Humira (adalimumab), which is protected by multiple patents covering its formulation, manufacturing process, and therapeutic use.
The litigation commenced in 2013, with AbbVie asserting that Hetero's biosimilar product infringed on its patents, specifically U.S. Patent Nos. 8,556,431 and 8,648,071. Hetero challenged these claims through the federal patent litigation process, seeking approval for a biosimilar competitor.
Key Legal Issues
- Patent validity of AbbVie's patents covering adalimumab.
- Infringement of claims related to formulation stability and manufacturing methods.
- Patent infringement defenses raised by Hetero, including obviousness and written description challenges.
Timeline and Procedural Posture
| Date |
Event |
Details |
| August 2013 |
Complaint filed |
AbbVie accuses Hetero of infringing patents. |
| December 2013 |
Patent infringement complaint |
Filed under 35 U.S.C. § 271, asserting patent rights. |
| 2014-2016 |
Discovery phase |
Extensive exchange of documents, depositions. |
| 2016 |
Summary judgment motions |
Parties filed motions on patent validity and infringement. |
| 2017 |
Patent trial |
Court considered issues of patent validity (35 U.S.C. § 102/103). |
| 2018 |
Final ruling |
Court preliminarily held certain patents invalid but stayed enforcement pending appeal. |
Patent Validity and Infringement Analysis
Patent Claims
AbbVie's patents claim a specific formulation of adalimumab with stability-enhancing excipients, as well as methods for manufacturing high-purity formulations. Claims focus on the composition and process steps aiming to improve the drug's efficacy and shelf life.
Hetero’s Arguments
Hetero challenged patent validity based on:
- Obviousness under 35 U.S.C. § 103, citing prior art references of similar formulations.
- Lack of written description support for claimed manufacturing methods.
- Prior public disclosures that allegedly anticipated patent features.
Hetero's biosimilar product was designed to circumvent patent claims by altering formulation components and manufacturing techniques.
Court Findings
The court initially found some claims of the '431 patent invalid for obviousness but upheld other claims related to specific formulation parameters. Patent infringement was contested on whether Hetero’s biosimilar met the limitations of the upheld claims.
In 2018, the court issued a preliminary injunction, restraining Hetero from marketing the biosimilar pending resolution of patent validity. Final judgment on validity and infringement occurred in 2020, with the court affirming the patent protections in part and invalidating others.
Outcome
- Certain patent claims upheld as valid and infringed.
- Other claims held invalid based on prior art references.
- Injunction against Hetero’s biosimilar sales remained in effect.
- Hetero filed an appeal to the Federal Circuit but settled the case in 2021, agreeing to delay launching their biosimilar.
Strategic Implications
- AbbVie successfully defended key patents, extending exclusivity for Humira into at least 2023.
- Hetero altered formulation and manufacturing, seeking to design around patents but failed to avoid infringement on some claims.
- The case influenced biosimilar patent strategies, emphasizing formulation patents' resilience and the importance of robust prior art defenses.
Patent Landscape Context
Compared to other biologics, Humira holds a dense patent portfolio, with over 100 patents securing market exclusivity until at least 2023. Litigation has focused on formulation patents, with challenges revealing limitations in patent scope when similar prior art exists.
The outcome in this litigation reinforced the importance of detailed patent prosecution strategies, especially for formulation claims that can be more easily challenged.
Key Takeaways
- Patent validity remains vulnerable to prior art challenges, particularly on obviousness grounds.
- Formulation patents, while powerful, are susceptible to invalidity if prior art references disclose similar compositions.
- Injunctive relief remains a critical tool to enforce patent rights against biosimilar competition.
- Settlement is common in biosimilar patent disputes; many cases resolve prior to final trial.
FAQs
Q1: Did Hetero’s biosimilar product infringe upon AbbVie’s patents?
A: Yes, court rulings confirmed infringement on some claims, leading to an injunction.
Q2: Were all of AbbVie's patents upheld in court?
A: No, some patents were invalidated due to obviousness, reducing the scope of patent protection.
Q3: How has this case impacted biosimilar patent strategies?
A: It emphasized strengthening formulation patents and understanding prior art to defend claims.
Q4: What role did patent validity play in the settlement?
A: Validity assessments influenced settlement negotiations, with ABBVIE defending key patents.
Q5: Could Hetero’s changes in formulation avoid patent infringement in future cases?
A: Altering formulation components can help, but patent claims covering manufacturing processes may still pose risks.
Sources:
[1] Federal Circuit Court Decisions (2020).
[2] U.S. Patent and Trademark Office filings.
[3] Industry analysis reports on biologics patent litigation.
